FTRE vs NVCT
FTRE: Fortrea is a global contract research organization that accelerates the delivery of life-changing treatments by providing flexible, science-driven clinical development solutions to pharmaceutical and medical device partners. NVCT: Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including breast, lung, prostate, and pancreatic cancers.
Side-by-side fundamentals
| Metric | FTRE | NVCT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.49 | $19.29 | |
| Market cap as of 2026-07-23 | $1.7B | $608M | |
| PEG as of 2026-07-23 | 0.50 | -0.89 | NVCT lower |
| Net margin as of 2026-07-23 | -16.5% | n/a | |
| Gross margin as of 2026-07-23 | +18.9% | n/a | |
| Operating margin as of 2026-07-23 | -13.1% | n/a | |
| ROE as of 2026-07-23 | -79.1% | -147.8% | FTRE higher |
| ROA as of 2026-07-23 | -16.3% | -90.8% | FTRE higher |
| Debt / equity as of 2026-07-23 | 2.00 | 0.00 | NVCT lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -1.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 2.02 | -0.24 | |
| 1-year return as of 2026-07-22 close | +218.8% | +139.1% | FTRE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.